Maiwei Biosciences raised HK$1.3 billion in its Hong Kong IPO.

According to regulatory filing, Meiwu Biotechnology Limited raised a total of HK$1.3 billion in funds through its listing in Hong Kong. The public offering portion in Hong Kong was oversubscribed by 481.71 times.